MINIMAL RESIDUAL DISEASE
Clinical trials for MINIMAL RESIDUAL DISEASE explained in plain language.
Never miss a new study
Get alerted when new MINIMAL RESIDUAL DISEASE trials appear
Sign up with your email to follow new studies for MINIMAL RESIDUAL DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New strategy zaps lung cancer spots before they grow
Disease control CompletedThis study tested whether giving focused treatments (like heat or freezing) to cancer spots in the body can help control advanced lung cancer that has spread. The approach uses a blood test to find tiny bits of cancer DNA (minimal residual disease) and treats when levels rise. 37…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 17, 2026 10:43 UTC
-
Immune cells take on tough leukemia in early trial
Disease control CompletedThis early-phase study tested a new therapy made from lab-grown natural killer (NK) cells in 2 adults with acute myeloid leukemia (AML) that had come back or was hard to treat. The goal was to see if the treatment is safe and to get a first look at whether it can reduce signs of …
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New immunotherapy targets hidden leukemia cells to prevent relapse
Disease control CompletedThis study tested a drug called blinatumomab in 36 adults with B-cell acute lymphoblastic leukemia whose cancer was in remission but still had a small number of leukemia cells detectable (minimal residual disease). The goal was to see if blinatumomab could help keep the cancer fr…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New immunotherapy targets lingering cancer cells in pancreatic and other tumors
Disease control CompletedThis early-phase trial tested an experimental immunotherapy called ELI-002 in 25 people with KRAS-mutated pancreatic, colorectal, lung, ovarian, or bile duct cancers who had minimal residual disease (small amounts of cancer left after standard treatment). The goal was to see if t…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE1 • Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated May 04, 2026 16:22 UTC